Mycofit (Mycophenolate Mofetil)

Mycophenolate Mofetil is converted in the body to mycophenolic acid, which selectively blocks the enzyme inosine monophosphate dehydrogenase (IMPDH). This inhibition curtails the synthesis of guanosine nucleotides, a building block essential for the proliferation of T‑ and B‑lymphocytes, leading to reduced immune activity.

The appropriate dose of Mycofit is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and other clinical factors. Dosage regimens can vary widely, so patients should follow the exact instructions provided by their healthcare professional.

Mycofit is classified as Pregnancy Category X, indicating that it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as the drug can be excreted in breast milk and may affect the infant.

To order Mycofit, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

The primary alternative to Mycofit is azathioprine, another immunosuppressant. Mycophenolate Mofetil generally provides more potent inhibition of lymphocyte proliferation with a different side‑effect profile, often resulting in lower rates of certain toxicities such as hepatotoxicity, but it may carry a higher risk of gastrointestinal upset and infections.

Mycofit should be stored at temperatures below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight.

Mycofit is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The tablets (or other oral form) should be swallowed whole and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include severe infections, hematologic abnormalities such as anemia or leukopenia, and liver injury. Patients should promptly report fever, persistent sore throat, unusual bruising, yellowing of the skin or eyes, or any signs of infection to their clinician.

Mycofit is contraindicated in individuals who are pregnant, have known hypersensitivity to mycophenolate or any component of the formulation, or have severe uncontrolled infections. Caution is also advised for patients with significant renal or hepatic impairment, and it should be avoided in those receiving live vaccines.